Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
Cobolimab plus dostarlimab showed preliminary efficacy and tolerability in a subset of patients with locally advanced/metastatic NSCLC. See related article by Davar et al., p. 3433.
Authors
- Theo Borgovan
- Srimoyee Ghosh
- Angela Waszak
- Martin Gutierrez (ORCID: https://orcid.org/0000-0003-3156-3159)
- Shyam Srivats
- Zeynep Eroglu (ORCID: https://orcid.org/0000-0002-2307-7030)
- Diwakar Davar (ORCID: https://orcid.org/0000-0002-7846-8055)
- Niranjan Yanamandra
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
- Hailei Zhang
- Brian Di Pace (ORCID: https://orcid.org/0000-0003-0568-9970)
- Antoni Ribas (ORCID: https://orcid.org/0000-0003-3669-8458)
- T. Wang
- Mohammed Milhem (ORCID: https://orcid.org/0000-0003-4663-6824)
- Arindam Dhar (ORCID: https://orcid.org/0000-0002-7929-0877)
- Carlos Becerra
Institutions
- University of Iowa (US)
- University of California, Los Angeles (US)
- Moffitt Cancer Center (US)
- University of New Haven (US)
- GlaxoSmithKline (United States) (US)
- BG Medicine (United States) (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Hackensack Meridian Health (US)
- The US Oncology Network (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0806
- Citations
- 5
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 5.23